Ticker Details
Alkermes plc Ordinary Shares Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.
IPO Date:	August 1, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.81B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 1.86%
Avg Daily Range (30 D):	$0.62 | 2.03%
Avg Daily Range (90 D):	$0.48 | 1.57%

Institutional Daily Volume
Avg Daily Volume:	1.09M
Avg Daily Volume (30 D):	2.2M
Avg Daily Volume (90 D):	1.71M

Trade Size
Avg Trade Size (Sh.):	114
Avg Trade Size (Sh.) (30 D):	71
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	14,215
Avg Institutional Trade:	$2.58M
Avg Institutional Trade (30 D):	$4.06M
Avg Institutional Trade (90 D):	$4M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.43M
Avg Closing Trade (30 D):	$13.07M
Avg Closing Trade (90 D):	$11.45M
Avg Closing Volume:	183.7K

News

Feb 23, 2026 @ 3:26 PM Viridian Therapeutics Stock Up 75%, but One Fund J... Source: Jonathan Ponciano

Feb 23, 2026 @ 3:18 PM Spyre Therapeutics Stock Surges This Past Year as ... Source: Jonathan Ponciano

Feb 10, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces Outcome of the Co... Source: Globe Newswire

Jan 12, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces that Avadel Share... Source: Globe Newswire

Dec 3, 2025 @ 9:47 PM Announcement relating to despatch of Definitive Pr... Source: Globe Newswire

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$1.47	$.3	$1.47
Diluted EPS	$1.43	$.29	$1.43
Revenue	$1.48B	$384.55M	$1.48B
Gross Profit	$1.28B	$338.34M	$1.28B
Net Income / Loss	$241.66M	$49.34M	$241.66M
Operating Income / Loss	$253.96M	$58.1M	$253.96M
Cost of Revenue	$196.46M	$46.21M	$196.46M
Net Cash Flow	$828.63M	$503.33M	$828.63M
PE Ratio	23.41

Splits
May 15, 2000	2:1